FWCM
ASND icon

Ferguson Wellman Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Ferguson Wellman Capital Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$693K Hold
2,600
– – 0.01% 275
2026
Q1 		$595K Buy
+2,600
New +$583K 0.01% 272

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Ferguson Wellman Capital Management's ASND Position: Q2 2026 in Review

Ferguson Wellman Capital Management held its Ascendis Pharma A/S (ASND) position steady in Q2 2026 at 2,600 shares worth $693K. The position accounts for 0.01% of the portfolio, ranked #275.

Ferguson Wellman Capital Management first reported a position in ASND in Q1 2026 and has held it in 2 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Ferguson Wellman Capital Management held 2,600 shares of Ascendis Pharma A/S worth $693K as of Q2 2026.
  • Ferguson Wellman Capital Management left its Ascendis Pharma A/S share count unchanged in Q2 2026.
  • Ascendis Pharma A/S made up 0.01% of Ferguson Wellman Capital Management's portfolio in Q2 2026, its #275 holding.
  • Ferguson Wellman Capital Management first reported a position in Ascendis Pharma A/S in Q1 2026 and has held it in 2 quarters since.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Ferguson Wellman Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.